IMRX Immuneering Corporation Class A Common Stock
XNAS
3.81
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
IMRX
$3.81
—
Key stats
$3.81
- 52-Week Range
- $3.38 – $8.48
- YTD
- -42.47%
- Straddle Price
- $2.68
- P/C Vol Ratio
- 13.17
- Market Cap
- $0.2B
- Open
- $3.72
- Day Range
- $3.70 – $3.83
- Volume
- 127,281
- Prev Close
- $3.74
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 1.11 |
| Cost of Equity (CAPM) | 11.26% (VRP-adj) |
| WACC | 11.27% |
| Volatility Risk Premium | +209.1pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -30.0% |
| Book / Price | 95.8% — banking bias active (P/B is primary) |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $4.47 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $3.89 |
| Bollinger Width / SMA20 | 651.0% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: ABT, NVS, PFE
(SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
89%
20-Day Fair Value
≈ by Nov 20, 2026
$3.79
α +0.4%
rank 93%
conviction
25%
40-Day Fair Value
≈ by Dec 21, 2026
$3.89
α +2.9%
rank 95%
conviction
83%
60-Day Fair Value
≈ by Jan 19, 2027
$3.92
α +3.7%
rank 94%
conviction
89%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 39.6× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 19.0× · 3 peers |
| Peer P/B | $12.43 | 20% | median 3.5× · 3 peers |
| Peer P/S | n/a | 0% | median 3.8× · 3 peers |
| Market Anchor (SMA50) | $4.47 | 80% | stability 76% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.2B
- Employees
- 57
- List Date
- 2021-07-30
- CIK
- 0001790340
- Next Earnings
- 2026-11-11
- EPS Forecast
- ($0.29) (3 est.)
- Headquarters
- Cambridge, MA
- Homepage
- https://www.immuneering.com
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -41.14% | 4.49% | -19.81% | -12.22% | -30.06% | -19.75% |
| Feb | -- | -27.62% | 17.27% | 7.92% | -12.23% | 3.53% | -2.23% |
| Mar | -- | -7.83% | 90.39% | -53.01% | 2.70% | 5.40% | 7.53% |
| Apr | -- | -33.20% | 18.83% | -48.36% | -20.67% | -1.69% | -17.02% |
| May | -- | -17.04% | -25.84% | -9.15% | 32.56% | 7.45% | -2.40% |
| Jun | -- | 36.27% | 7.64% | -7.25% | 80.21% | 11.01% | 25.58% |
| Jul | 0.00% | 30.40% | 4.42% | -3.42% | 0.00% | -17.23% | 2.36% |
| Aug | 43.94% | -13.76% | -15.32% | -17.78% | 70.62% | 19.66% | 14.56% |
| Sep | 1.92% | 106.04% | -14.67% | 105.79% | 16.86% | -15.57% | 33.40% |
| Oct | -6.23% | -7.42% | -0.71% | -19.83% | 8.02% | -6.20%* | -5.39% |
| Nov | -15.69% | -53.48% | 1.23% | 11.76% | 16.77% | -- | -7.88% |
| Dec | -19.59% | -24.92% | -11.12% | 4.76% | -7.19% | -- | -11.61% |
| Total | -6.74% | -77.78% | 49.16% | -72.86% | 250.00% | -29.80% | 18.66% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $3.86
SMA 50: $4.44
SMA 200: $4.85
Current: $3.81
EMA 12: $3.77
EMA 26: $3.97
MACD: -0.2019 | Signal: 0.0270
BEARISH
ADX (14): 32.25
TREND
+DI: 17.61
−DI: 26.69
Momentum Oscillators
RSI (14): 43.36
NEUTRAL
Stoch %K: 49.82
Stoch %D: 41.75
Williams %R: -41.89
Volume & Volatility
BB Upper: $4.30
BB Lower: $3.41
NEUTRAL
OBV: -11,718,719
Vol SMA 20: 694,265
Vol ROC: -93.63%
ATR: $0.19
True Range: $0.13
HV 20: 52.8%
HV 30: 51.4%
HV 60: 50.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report: IMRX
Executive Summary
BULLISH (Confidence Level: 8/10)
Key drivers: Positive earnings expectations, FDA approval in metastatic pancreatic cancer, and a strong momentum signal from the MACD.
Primary risks:
- High volatility, as indicated by the IV premium vs HV30
- The stock's beta is higher than the market average, indicating more price movement relative to the overall market
Investment thesis: IMRX has significant growth potential due to its FDA-approved product in metastatic pancreatic cancer and strong momentum signals.
Recent news sentiment impact: Positive headlines from recent FDA approval and clinical trial data have driven the stock's recent rally.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): Bullish, Medium-term (1-3 months): Bullish, Long-term (3-12 months): Bullish
Support/Resistance Levels:
- SMA 20: $4.88 (support)
- EMA 12: $5.10 (resistance)
Momentum Signals:
- RSI interpretation: Neutral (58.82), not oversold or overbought
- MACD signal: Bullish momentum, with a bullish crossover above the signal line
- Bollinger Bands position: Neutral, with price near the middle band
Volume Analysis: Volume trends and institutional interest signals:
- Volume SMA 20: 632091.98 (increasing), indicating rising institutional interest
- OBV: 219281381.36 (strongly positive)
News & Sentiment Analysis
Recent Headlines Summary: Positive headlines from FDA approval, clinical trial data, and recent stock market activity have driven the stock's rally.
Sentiment Assessment: Positive sentiment dominates, with 4 out of 6 recent news articles having a positive tone.
Catalyst Identification: Upcoming events: Earnings announcements and regulatory approvals will continue to drive the stock's momentum.
Market Narrative: The recent FDA approval has created a strong narrative for IMRX, driving the stock higher. This sentiment is reflected in the MACD signal and RSI interpretation.
Risk & Volatility Assessment
Beta Interpretation: High risk relative to the market (beta = 1.16), indicating more price movement.
Volatility Regime: Current volatility level is above average, with a historical volatility range of HV20: 46.8%, HV30: 52.9%, and HV60: 58.3%.
Options Market Signals: IV Rank: Low (16.8%), indicating historically low volatility.
Downside Protection: Support levels are established at $4.88 (SMA 20) and $4.08 (Bollinger Bands lower band).
Market Context & Positioning
Sector Performance: IMRX has outperformed its sector in recent months, with a relative strength index of R-squared = 0.76.
Institutional Activity: Institutional interest is increasing, as indicated by rising volume trends and OBV signals.
Correlation Analysis: IMRX has a moderate correlation with the market (R-squared = 0.46).
Relative Valuation: IMRX is trading within its historical range, with some room for further upside.
Key Levels & Action Items
Critical Price Levels:
- Support: $4.88 (SMA 20), $4.08 (Bollinger Bands lower band)
- Resistance: $5.10 (EMA 12), $5.68 (Bollinger Bands upper band)
Breakout/Breakdown Levels: A break above $5.68 or below $4.08 could trigger significant moves.
Time-Sensitive Catalysts: Upcoming earnings announcements and regulatory approvals will continue to drive the stock's momentum.
Risk Management: Stop-loss levels can be set at $4.88 (SMA 20) for a risk-reward ratio of approximately 2:1.
Overall, IMRX has strong technical signals, positive news sentiment, and increasing institutional interest. The stock's beta is higher than average, indicating more price movement relative to the market. With a bullish trend direction and momentum signals, IMRX presents an attractive investment opportunity with a confidence level of 8/10.
Generated
News
All IMRX news →
Earnings History
4 of 4 under expected move
Avg Expected Move
49.65%
Avg Actual Move
2.50%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2025-11-12 | unknown | 22.28% | 2.57% | 0.12x | Within |
| 2026-03-06 | unknown | 13.60% | 5.44% | 0.40x | Within |
| 2026-05-18 | unknown | 29.26% | 0.41% | 0.01x | Within |
| 2026-08-05 | unknown | 133.47% | 1.59% | 0.01x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
IMRX Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $2.68
7-DTE Move: $2.68
Days to Exp: 29 (2026-11-20)
Options Flow
Call Volume: 36
Put Volume: 474
P/C Volume: 13.167
BEARISH
Call OI: 557
Put OI: 325
P/C OI: 0.583
Total OI: 882
ATM Options Pricing
ATM Call: $0.20
ATM Put: $2.48
Call %: 5.3%
Put %: 65.0%
Chain Summary
Chain Volume: 782
Chain OI: 3,941
Last Updated: 10/22/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 65th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
65%
vs own history
GEX tilt
+0.64
OI-weighted, today
Vanna tilt
+0.59
δ-sensitivity to IV
Charm tilt
-0.84
δ-decay vs time
Vanna tilt +0.59: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.84: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 5 ATM contracts, 3k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
ATM 385.1% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$2.68Oct 22
Beta Analysis
Risk Metrics
Beta: 1.1091
Alpha: -15.00%
Correlation: 0.1755
R-Squared: 3.1%
Stock Volatility: 80.4%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own IMRX
2 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $1.9M | #2960 of 6285 | -13.6% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $1.6M | #2674 of 3716 | -70.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
IMRX Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 53,259,488 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
3 filers$2.69M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $1.41M | 52.37% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $915.66K | 34.02% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $366.27K | 13.61% | 2026-06-30 |
3 filers$997.00K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $544.41K | 54.60% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $307.38K | 30.83% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $145.21K | 14.56% | 2026-06-30 |
IMRX Insider Trading (Form 4)
Latest: 2026-07-17Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-07-17 | Andrew Gengos | Chief Financial Officer | Grant (A) | +650,000 opt | — | EDGAR | |
| 2026-06-24 | Benjamin J. Zeskind | PRESIDENT AND CEO | Buy (P) | +2,400 | $4.56 | $10.9K | EDGAR |
| 2026-06-16 | Brett Matthew Hall | CHIEF SCIENTIFIC OFFICER | Buy (P) | +6,035 | $4.15 | $25.0K | EDGAR |
| 2026-06-11 | Laurie Keating | Director | Grant (A) | +33,350 opt | — | EDGAR | |
| 2026-06-11 | Robert J Carpenter | Director | Grant (A) | +33,350 opt | — | EDGAR | |
| 2026-06-11 | Diana Hausman | Director | Grant (A) | +33,350 opt | — | EDGAR | |
| 2026-06-11 | Peter Feinberg | Director | Grant (A) | +33,350 opt | — | EDGAR | |
| 2026-06-11 | Thomas J. Schall | Director | Grant (A) | +33,350 opt | — | EDGAR | |
| 2026-03-17 | Leah R Neufeld | CHIEF PEOPLE OFFICER | Award (A) | +3,628 | $4.29 | $15.6K | EDGAR |
| 2026-02-05 | Leah R Neufeld | CHIEF PEOPLE OFFICER | Grant (A) | +140,000 opt | — | EDGAR | |
| 2026-02-05 | Mallory Morales | SVP Finance, CAO | Grant (A) | +140,000 opt | — | EDGAR | |
| 2026-02-05 | Igor Matushansky | Chief Medical Officer | Grant (A) | +140,000 opt | — | EDGAR | |
| 2026-02-05 | Brett Matthew Hall | CHIEF SCIENTIFIC OFFICER | Grant (A) | +344,000 opt | — | EDGAR | |
| 2026-02-05 | Harold Eugene Brakewood | Chief Business Officer | Grant (A) | +140,000 opt | — | EDGAR | |
| 2026-02-05 | Michael Bookman | CHIEF LEGAL OFFICER, SECRETARY | Grant (A) | +176,000 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
IMRX Insider Holdings
12 insiders · @ $3.81
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Benjamin J. Zeskind | PRESIDENT AND CEO | 3,210,179 | $12.23M | $254.5K | 15 | 2026-06-24 |
| 2 | Robert J Carpenter | Director | 823,839 | $3.14M | $4.88M | 6 | 2026-06-11 |
| 3 | Brett Matthew Hall | CHIEF SCIENTIFIC OFFICER | 382,531 | $1.46M | $128.8K | 14 | 2026-06-16 |
| 4 | Peter Feinberg | Director | 292,207 | $1.11M | $5.20M | 19 | 2026-06-11 |
| 5 | Thomas J. Schall | Director | 74,530 | $284.0K | $232.5K | 8 | 2026-06-11 |
| 6 | Ann E Berman | Director | 67,465 | $257.0K | $214.3K | 9 | 2025-06-16 |
| 7 | Leah R Neufeld | CHIEF PEOPLE OFFICER | 29,598 | $112.8K | $29.5K | 12 | 2026-03-17 |
| 8 | Mallory Morales | SVP Finance, CAO | 27,533 | $104.9K | $5.9K | 11 | 2026-02-05 |
| 9 | Laurie Keating | Director | 14,000 | $53.3K | $140.0K | 10 | 2026-06-11 |
| 10 | Harold Eugene Brakewood | Chief Business Officer | 11,050 | $42.1K | $39.8K | 8 | 2026-02-05 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
IMRX Board & Officers
As of SEC filings through Jul 17, 2026Directors 7
- Ann E Berman · since Jul 29, 2021
- Benjamin J. Zeskind · since Jul 29, 2021
- Laurie Keating · since Jul 29, 2021
- Peter Feinberg · since Jul 29, 2021
- Robert J Carpenter · since Jul 29, 2021
- Diana Hausman · since Jan 14, 2022
- Thomas J. Schall · since Mar 11, 2024
Officers 8
- Benjamin J. Zeskind · President and CEO · since Jul 29, 2021
- Andrew Gengos · Chief Financial Officer · since Jul 16, 2026
- Brett Matthew Hall · Chief Scientific Officer · since Jul 29, 2021
- Leah R Neufeld · Chief People Officer · since Oct 17, 2022
- Harold Eugene Brakewood · Chief Business Officer · since Mar 27, 2023
- Mallory Morales · Chief Accounting Officer · listed since Feb 2024
- Michael Bookman · Chief Legal Officer, Secretary · listed since Feb 2024
- Igor Matushansky · Chief Medical Officer · since Mar 17, 2025
Changes in the last 10 years (38)
| Jul 16, 2026 | Andrew Gengos became Chief Financial Officer |
| Feb 5, 2026 | Benjamin J. Zeskind no longer listed as a 10% owner in SEC filings |
| Mar 17, 2025 | Igor Matushansky became Chief Medical Officer |
| Apr 3, 2024 | Cormorant Private Healthcare Fund III LP reported in an SEC filing no longer being a 10% owner |
| Apr 3, 2024 | Cormorant Global Healthcare Master Fund, LP reported in an SEC filing no longer being a 10% owner |
| Apr 3, 2024 | Cormorant Asset Management, LP reported in an SEC filing no longer being a 10% owner |
| Apr 3, 2024 | Bihua Chen reported in an SEC filing no longer being a 10% owner |
| Mar 11, 2024 | Thomas J. Schall became a director |
| Feb 9, 2024 | Michael Bookman listed as Chief Legal Officer, Secretary (previously General Counsel and Secretary) in SEC filings |
| Feb 9, 2024 | Mallory Morales listed as Chief Accounting Officer (previously Vice President, Finance) in SEC filings |
| Apr 24, 2023 | Cormorant Private Healthcare Fund III LP first listed as a 10% owner in an SEC filing |
| Apr 24, 2023 | Cormorant Global Healthcare Master Fund, LP first listed as a 10% owner in an SEC filing |
| Apr 24, 2023 | Cormorant Asset Management, LP first listed as a 10% owner in an SEC filing |
| Apr 24, 2023 | Bihua Chen first listed as a 10% owner in an SEC filing |
| Mar 27, 2023 | Harold Eugene Brakewood became Chief Business Officer |
| Oct 17, 2022 | Leah R Neufeld became Chief People Officer |
| Aug 11, 2022 | Mallory Morales became Vice President, Finance |
| Jul 20, 2022 | The company announced the departure of Biren Amin as CFO, Treasurer in an SEC filing |
| Jan 14, 2022 | Diana Hausman became a director |
| Aug 5, 2021 | Cormorant Private Healthcare Fund III LP reported in an SEC filing no longer being a 10% owner |
| Aug 5, 2021 | Cormorant Global Healthcare Master Fund, LP reported in an SEC filing no longer being a 10% owner |
| Aug 5, 2021 | Cormorant Asset Management, LP reported in an SEC filing no longer being a 10% owner |
| Aug 5, 2021 | Bihua Chen reported in an SEC filing no longer being a 10% owner |
| Jul 29, 2021 | Scott Barrett became Chief Medical Officer |
| Jul 29, 2021 | Robert J Carpenter became a director |
| Jul 29, 2021 | Peter Feinberg became a director |
| Jul 29, 2021 | Michael Bookman became General Counsel and Secretary |
| Jul 29, 2021 | Laurie Keating became a director |
| Jul 29, 2021 | Cormorant Private Healthcare Fund III LP became a 10% owner |
| Jul 29, 2021 | Cormorant Global Healthcare Master Fund, LP became a 10% owner |
| Jul 29, 2021 | Cormorant Asset Management, LP became a 10% owner |
| Jul 29, 2021 | Brett Matthew Hall became Chief Scientific Officer |
| Jul 29, 2021 | Biren Amin became CFO, Treasurer |
| Jul 29, 2021 | Bihua Chen became a 10% owner |
| Jul 29, 2021 | Benjamin J. Zeskind became a director |
| Jul 29, 2021 | Benjamin J. Zeskind became a 10% owner |
| Jul 29, 2021 | Benjamin J. Zeskind became President and CEO |
| Jul 29, 2021 | Ann E Berman became a director |
Not reported recently (1)
- Scott Barrett · Last reported as Chief Medical Officer in an SEC filing dated Feb 17, 2023
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
IMRX Proposed Insider Sales (Form 144)
Latest: 2025-09-23
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2025-09-23 | BERMAN ANN E | Director | 14,000 | $136.1K | 2025-09-23 | Fidelity Brokerage Services LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
21 ETFs hold IMRX
21 shown · $20.87M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $6.6M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $5.2M | $75.1B | 2026-10-20 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $2.6M | — | 2026-09-30 |
| 4 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.01% | $2.0M | $13.7B | 2026-10-20 |
| 5 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.02% | $1.6M | $11.0B | 2026-10-20 |
| 6 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.01% | $1.3M | — | 2026-09-30 |
| 7 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.05% | $637,505 | $1.2B | 2026-10-20 |
| 8 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.01% | $256,441 | $3.1B | 2026-10-20 |
| 9 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.02% | $215,450 | — | 2026-09-30 |
| 10 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.02% | $190,790 | $1.0B | 2026-10-20 |
| 11 | RSSL Global X Russell 2000 ETF | Global X | 0.01% | $97,629 | — | 2026-10-21 |
| 12 | IBBQ Invesco Nasdaq Biotechnology ETF | Nport | 0.03% | $19,658 | — | 2026-05-31 |
| 13 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $18,767 | — | 2026-09-30 |
| 14 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $13,421 | — | 2026-10-20 |
| 15 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.01% | $12,200 | — | 2026-10-21 |
| 16 | URTY ProShares UltraPro Russell2000 | ProShares | 0.00% | $9,500 | — | 2026-10-21 |
| 17 | BIB ProShares Ultra NASDAQ Biotechnology | ProShares | 0.01% | $9,294 | — | 2026-10-21 |
| 18 | UWM ProShares Ultra Russell2000 | ProShares | 0.00% | $6,156 | — | 2026-10-21 |
| 19 | RESM Columbia Research Enhanced Small Cap ETF | Nport | 0.01% | $324 | — | 2026-06-30 |
| 20 | HDG ProShares Hedge Replication ETF | ProShares | 0.00% | $254 | — | 2026-10-21 |
| 21 | RB ProShares Russell 2000 Dynamic Buffer ETF | ProShares | 0.01% | $82 | — | 2026-10-21 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.93
TTM Revenue
—
TTM Net Income
$-57.28M
TTM Op. Cash Flow
$-56.75M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-17.27M | $-0.27 | $-16.50M |
| Q1 '26 | 2026-03-31 | — | $-13.46M | $-0.21 | $-18.43M |
| Q4 '25 | 2025-12-31 | — | $-11.58M | $-0.07 | $-9.84M |
| Q3 '25 | 2025-09-30 | — | $-14.96M | $-0.38 | $-11.98M |
| Q2 '25 | 2025-06-30 | — | $-14.43M | $-0.40 | $-9.45M |
| Q1 '25 | 2025-03-31 | — | $-15.05M | $-0.42 | $-14.08M |
| Q4 '24 | 2024-12-31 | — | $-18.05M | $-0.59 | $-14.51M |
| Q3 '24 | 2024-09-30 | — | $-14.60M | $-0.49 | $-13.47M |
| Q2 '24 | 2024-06-30 | — | $-14.08M | $-0.47 | $-11.53M |
| Q1 '24 | 2024-03-31 | — | $-14.31M | $-0.49 | $-15.49M |
| Q4 '23 | 2023-12-31 | — | $-15.08M | $-0.52 | $-11.78M |
| Q3 '23 | 2023-09-30 | — | $-12.60M | $-0.43 | $-12.03M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-05
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.06
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-30.0%
ROA
-28.3%
Div Yield
0.00%
FCF Yield
-28.19%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$201.32M
as of 2026-10-22
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
15.49M
SI % of Float
27.69%
Days to Cover
24.22
Short Vol Ratio
45.2%
Free Float
55.96M
Float %
86.5%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-08-14